Cybin, now Helus Pharma

Cybin said in January 2025 that it would rebrand as Helus Pharma and shift its U.S. listing to Nasdaq. That means the company’s official public identity changed, but the older Cybin name still matters for continuity across reporting, stock-market references, and trial-program history.

That continuity problem got sharper in April 2026. Helus had only just installed Michael Cola as chief executive in February, then said on April 20 that Cola was stepping down effective immediately at the request of the board and that co-founder and executive chairman Eric So would again serve as interim CEO. The company kept investor attention on Phase 3 continuity, but the public explanation for the reversal stayed notably thin.

Continuity and naming

The rebrand is not just cosmetic. It changes the official site, investor-relations surface, and how newer program materials are titled. This page keeps the legacy cybin route while making the current Helus identity explicit, so readers can connect the older company record to the current one without breaking continuity.

Clinical program

Helus’s own program materials now describe HLP003, formerly referred to as CYB003, as a deuterated novel serotonergic agonist with FDA Breakthrough Therapy Designation for adjunctive treatment of major depressive disorder. The company’s clinical-trials page explicitly notes that HLP003 was formerly CYB003, which helps close the naming gap between older Cybin-era reporting and newer Helus-era program language.

The Phase 3 PARADIGM program, outlined in Helus investor materials, organizes the depression effort into APPROACH, EMBRACE, and EXTEND. Public registry coverage through NCT06564818 helps anchor the program in a checkable trial record rather than only investor copy.

Leadership whiplash in April 2026

The more structurally important update is the leadership break. Helus introduced Michael Cola on February 10 as the operator who would lead the company’s next phase of scale, execution, and commercialization planning. Sixty-nine days later, the company said Cola was leaving at the board’s request and that Eric So would resume the interim chief executive role while the search restarted.

That does not automatically change the Phase 3 program. It does change how the company should be read. A board-requested CEO removal that fast, with no substantive public explanation, becomes part of the company record whether or not the trial calendar stays intact.

Why this page matters

Cybin/Helus remains one of the more advanced psychedelic-compound developers and one of the clearest examples of how naming continuity, investor communications, clinical-trial status, and governance can drift apart if the dossier is not maintained carefully. The route stays cybin, but the live company, program language, and management story now belong to Helus.